KRYS - Buying The Dip In Abeona Therapeutics After The Recent Manufacturing-Related CRL
2024-05-02 17:50:00 ET
Summary
- Abeona Therapeutics is a gene therapy company with a lead product candidate, Pz-cel, for recessive epidermolysis bullosa, or RDEB.
- Pz-cel has shown higher efficacy than the competition in treating larger skin lesions in RDEB.
- Despite receiving a complete response letter from the FDA, Abeona believes the manufacturing issues can be resolved and plans to submit a response by Q3 this year.
- The stock is likely to bounce back to level before the CRL when the manufacturing issues are resolved and FDA approves the treatment.
Abeona Therapeutics ( ABEO ) is a gene therapy company based in Cleveland, Ohio. The company's lead product candidate is Pz-cel, a gene therapy for recessive epidermolysis bullosa, RDEB....
Buying The Dip In Abeona Therapeutics After The Recent Manufacturing-Related CRL